Angiogenesis , the formation of new blood vessels from pre existing ones, contributes to physiological and pathophysiological conditions. Pathophysiological angiogenesis is associated with several long-term complications of disease such as diabetic retinopathy and nephropathy, endometriosis, hypertension and tumor development while physiological angiogenesis is involved in wound healing, ovulation and menstrual cycles.
Angiogenesis , the formation of new blood vessels from pre existing ones, contributes to physiological and pathophysiological conditions. Pathophysiological angiogenesis is associated with several long-term complications of disease such as diabetic retinopathy and nephropathy, endometriosis, hypertension and tumor development while physiological angiogenesis is involved in wound healing, ovulation and menstrual cycles. The process of angiogenesis depends on the balance of many stimulating or inhibiting factors. The key factor that regulates proliferation and migration of endothelial cells is the Vascular Endothelial Growth Factor (VEGF). Angiogenic therapy includes inhibition of abnormal angiogenesis in some conditions such as tumors or diabetes and stimulation of angiogenesis in conditions of ischemia, such as in ischemic heart disease or peripheral vascular disease.
Angiogenic and anti-angiogenic growth factors: The involvement of angiogenic (growth factors such as bFGF, VEGF, TGF) and anti-angiogenesis (such as thrombospondin-1, endostatin
Using animal models (tumor angiogenesis, hindlimb ischemia, …)
Evaluation of angiogenesis by immunohistochemistry, enzyme histochemistry, changes of angiogenic factors in serum/plasma and tissues.